Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) – New drug approval
July 18, 2017 – Gilead announced the FDA approval of Vosevi (sofosbuvir/velpatasvir/ voxilaprevir), for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor, or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
Top